Market Research Report
U.S. Advanced Wound Care Market by Product, Application, and End User : Opportunity Analysis and Industry Forecast, 2020-2027
|Published by||Allied Market Research||Product code||955615|
|Published||Content info||166 Pages
Delivery time: 2-3 business days
|U.S. Advanced Wound Care Market by Product, Application, and End User : Opportunity Analysis and Industry Forecast, 2020-2027|
|Published: July 1, 2020||Content info: 166 Pages||
U.S. Advanced Wound Care Market by Product (Infection Management, Exudate Management, Active Wound Care, Therapy Devices), Application (Chronic Wounds and Acute Wounds), and End User (Hospitals and Community Centers): Opportunity Analysis and Industry Forecast, 2020-2027.
The U.S. advanced wound care market was valued at $3.35 billion in 2019 and is expected to reach $4.97 billion by 2027, registering a CAGR of 9.9% from 2020 to 2027.
Advanced wound care products offer relief to patients suffering from chronic wounds, which takes more time to heal and are expensive to treat. Wound healing process can be facilitated in two different ways, which include traditional wound care (TWC) and advanced wound care (AWC). Advanced wound care products enable faster healing, owing to their efficiency & effectiveness in managing wounds.
Significant increase in prevalence of chronic diseases such as diabetes & obesity, rise in geriatric population, problems associated with traditional wound healing methods, and surge in adoption of evidence-based treatments such as silver dressings, hyperbaric oxygen, electrotherapy, and ultrasound for chronic wounds are the key factors that fuel growth of the U.S. advanced wound care market. Moreover, rise in awareness programs for advanced wound care treatment & management, attempts to reduce duration of the hospital stay to lower healthcare expenses, and rise in inclination toward wound care products that enhance therapeutic outcomes are other factors that contribute toward growth of the market.
The U.S. advanced wound care market is segmented into product, application, and end user. By product, the market is categorized into infection management, exudate management, active wound care, and therapy devices. The infection management is sub segmented into silver dressings, non-silver dressings, and collagens. The exudate management segment is further divided into hydrocolloid dressings, foam dressings, alginate dressings, and hydrogel dressings. The active wound care is subdivided into skin substitutes and growth factors. The skin substitute is further segmented into xenograft, allografts, and cell-based bioengineering. The therapy devices is further segmented into negative pressure wound therapy (NPWT), oxygen & hyperbaric oxygen equipment, electromagnetic therapy devices, and others. The applications covered in the study include chronic wounds and acute wounds. The chronic wounds segment is further segregated into pressure ulcers, diabetic foot ulcers, venous leg ulcers, and arterial ulcers. The acute wounds is further fragmented into burns & trauma, and surgical wounds. Depending on end user, the market is classified into hospitals and community health service centers.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists in identifying the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate country-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the U.S. advanced wound care market is provided.
KEY MARKET SEGMENTS
Silver Wound Dressings
Active Wound Care
Negative Pressure Wound Therapy (NPWT)
Oxygen and Hyperbaric Oxygen Equipment
Electromagnetic Therapy Devices
Diabetic Foot Ulcers
Venous Leg Ulcers
Burns & Trauma
By End User
Community Health Service Centers
KEY MARKET PLAYERS
3M (Acelity Inc.)
B Braun Melsungen AG
ConvaTec Group Plc
Essity AB (BSN Medical GmbH)
Integra Lifesciences (Derma sciences)
Molnlycke Health Care AB
Johnson & Johnson
Medline Industries, Inc.
Organogenesis Holdings Inc.
Smith & Nephew Plc.
The other players in the value chain include (profiles not included in the report):